Senaste nyheterna

25 Maj 2021 14:00

OnDosis completes a private placement of SEK 92 million led by Aeternum Capital

OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.

The private placement follows the successful expansion of the strategic collaboration between OnDosis and Tiefenbacher

25 Maj 2021 14:00

New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar

10 Februari 2021 15:46

New business partner and international recognition for OnDosis

OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the large

11 September 2020 16:00

OnDosis announces commitment of 30 MSEK raise from owners and DIG Investment

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, AstraZeneca Medtech spin-off OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment

10 September 2020 08:00

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. The collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines, digital therapeutics and intelligent dosing.

Presskontakt

Martin Olovsson

Presskontakt CEO Ondosis m.olovsson@ondosis.com +46 76-772 85 01